NCT05134415已完成不适用
A Randomized, Single-Blind, Two-Arm, Cross-Over Study to Compare Use of Two Tobacco and Two Menthol Flavor e-Liquids in Electronic Nicotine Delivery System Users
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Study product use - daily pod use
研究概览
简要总结
This study is being conducted to evaluate the impact of within-flavor category (tobacco and menthol) differences in e-liquid flavors on product use behaviors, nicotine uptake, and subjective effects by current ENDS consumers when used in a closed-system electronic nicotine delivery system (ENDS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Single (Participant)
盲法说明
Participants will be blinded to the specific tobacco or menthol flavor variant used during each study period.
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is 22 to 65 years of age, inclusive, at the time of consent.
- •Has used a closed-system ENDS product on most days during the 60 days prior to Screening (no use on up to 8 days total is allowed). Dual use with open-system products will be allowed provided that the closed-system is the predominant system used (based on self-reported volume of e-liquid used).
- •Reports a tobacco or menthol/mint flavored e-liquid as the most commonly used flavor (based on self-reported volume of e-liquid used) during the 30 days prior to screening.
- •Agrees to maintain product use described in Criteria 3 and 4 from Screening through Test Visit
- •Has a urine cotinine concentration ≥ 200 ng/mL at Screening.
- •Has an ECO concentration < 10 ppm at Screening and Test Visit
- •If female, must meet one of the following criteria:
- •If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first product use and during the study. An acceptable method of contraception includes one of the following:
- •Abstinence from heterosexual intercourse
- •Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
- •Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g., condom and spermicide) during the study.
- •If a female of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses).
- •Is willing to comply with the requirements of the study.
- •Provides voluntary consent to participate in the study as documented on the signed ICF.
排除标准
- •Has a history or presence of clinically significant uncontrolled gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that would jeopardize the safety of the subject or impact the validity of the study results.
- •Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results at Screening, including, but not limited to, the following:
- •Has a history of drug or alcohol abuse within 12 months of Screening.
- •Has a systolic BP <90 mmHg or >160 mmHg, diastolic BP <40 mmHg or >95 mmHg, or HR <40 bpm or >99 bpm at Screening.
- •Has previously been diagnosed with any form of cancer, except for basal cell or squamous epithelial carcinomas of the skin that have been resected.
- •Has been treated chronically for depression, diabetes, asthma, emphysema, or chronic obstructive pulmonary disease within 12 months of Test Visit
- •Has had an acute illness (e.g., upper respiratory infection, viral infection) within 14 days prior to Test Visit 1 that would jeopardize the safety of the subject or impact the validity of the study results.
- •Subjects who, in the judgment of the study physician, have recent or active COVID 19 infection, as evidenced by the following:
- •Endorsement of symptoms that could indicate COVID-19 during screening and/or
- •Body temperature ≥100.4°F and/or
- •Laboratory test results suggestive of active or recent exposure to SARS CoV
- •Has a BMI greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Screening.
- •Is allergic to or intolerant of components of the product e-liquid, including but not limited to, menthol, propylene glycol, or glycerin.
- •Has a positive urine drug or alcohol test at Screening..
- •If female, has a positive pregnancy test, is breastfeeding or lactating, or intends to become pregnant from Screening through Test Visit
- •Is a current combustible cigarette, cigar, or little cigar smoker at Screening (more than 5 product uses in the previous 30 days).
- •Has used other tobacco- or nicotine-containing products other than ENDS products (e.g., combustible cigarettes, cigars, or little cigars, snuff, pouches, chewing tobacco, nicotine inhalers, nicotine patches, nicotine sprays, nicotine lozenges, or nicotine gum) from 14 days prior to Test Visit
- •Has used any products for the purpose of smoking/vaping cessation, including, but not limited to, nicotine replacement therapies, varenicline (Chantix), or bupropion (Zyban) from 30 days prior to Screening through Test Visit
- •Draws aerosol from the usual brand ENDS into the mouth and throat but does not inhale as observed by the clinic staff during Screening.
- •Is postponing a planned vaping quit attempt in order to participate in the study.
- •Has donated plasma within 7 days prior to Test Visit
- •Has provided a whole blood donation, had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to Test Visit
- •Has participated in a previous clinical study for a tobacco product or an investigational drug, device, or biologic, within 30 days or 5 times the half-life of the product (whichever is longer) prior to Test Visit
- •Is or has a first-degree relative (e.g., spouse, parent, sibling, child) who is a current or former employee of a tobacco or ENDS manufacturer (including the Sponsor) or is a named party or class representative in litigation with the tobacco or ENDS industry.
- •Is or has a first-degree relative (e.g., spouse, parent, sibling, child) who is a current employee of the clinic site(s).
- •Has previously been withdrawn from or has completed this study.
- •In the opinion of an Investigator, the subject should not participate in this study.
结局指标
主要结局
Study product use - daily pod use
时间窗: 14 days
The number of pods used per day during the 14-day ambulatory period
次要结局
- Puff topography - duration of puffs(5 minutes)
- Study product use - e-liquid consumption per day(14 days)
- Puff topography - number of puffs(5 minutes)
- Puff topography - volume of puffs(5 minutes)
- Puff topography - inter-puff interval(5 minutes)
- Study product use - e-liquid consumption (PK session)(5 minutes)
- Subjective effects - overall acute urge to vape reduction(30 minutes)
- Subjective effects - time to maximum acute urge to vape reduction(30 minutes)
- Study product use - e-liquid consumption per pod(14 days)
- Puff topography - peak flow rate of puffs(5 minutes)
- Subjective effects - future intent to use product(14 days)
- Subjective effects - withdrawal symptoms(14 days)
- Nicotine uptake - overall nicotine uptake(30 minutes)
- Subjective effects - craving(14 days)
- Puff topography - average flow rate of puffs(5 minutes)
- Subjective effects - dependence(14 days)
- Subjective effects - maximum acute urge to vape reduction(30 minutes)
- Subjective effects - product effects(14 days)
- Nicotine uptake - time to maximum nicotine concentration(30 minutes)
- Safety and tolerability - adverse events(14 days)
- Nicotine uptake - maximum nicotine concentration(30 minutes)
- Safety and tolerability - product malfunction or misuse(14 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative BioavailabilityHealthy VolunteersNCT04735822Kadmon Corporation, LLC30
已完成
不适用
CSD1602: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From Two King Size Menthol Cigarette ProductsSmokingNCT03063034RAI Services Company39
已完成
不适用
CSD1603: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From 100s Menthol Cigarette ProductsSmokingNCT03063047RAI Services Company29
已完成
不适用
Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to itPharmacokineticsNCT03953183Philip Morris Products S.A.60
已完成
不适用
Comparative Acceptability of Tobacco and Menthol Flavored E-cigarettesTobacco Use DisorderNCT04996940University of Kansas Medical Center52